Assess whether RWE can replace or only supplement an RCT (7fe172)

Situation

After a payer demanding RWE the protocol cannot generate, disproportionate reporting signal workbook is what RWE evidence-strategy director can touch in an RWE group proposing a post-marketing study instead of a new RCT. Pharma & Life Sciences will live with RWE can replace versus Only supplement an RCT on this Pharmacovigilance file.

Decision

RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT must choose RWE can replace / Only supplement an RCT using disproportionate reporting signal workbook after a payer demanding RWE the protocol cannot generate.

Hypotheses to test

• RWE evidence-strategy director can defend RWE can replace from disproportionate reporting signal workbook after a payer demanding RWE the protocol cannot generate in a Pharma & Life Sciences challenge.
• RWE evidence-strategy director cannot defend RWE can replace from disproportionate reporting signal workbook; Only supplement an RCT is what the extract actually supports after a payer demanding RWE the protocol cannot generate.
• A payer demanding RWE the protocol cannot generate never reached the population in disproportionate reporting signal workbook — reopen intake, do not close RWE can replace or.
• Two facts in disproportionate reporting signal workbook after a payer demanding RWE the protocol cannot generate conflict for RWE evidence-strategy director; hold this Pharmacovigilance file.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on RWE can replace or.
• Check whether disproportionate reporting signal workbook supports the labeled claim RWE evidence-strategy director would keep.
• For this Pharma & Life Sciences Pharmacovigilance file, read disproportionate reporting signal workbook against a payer demanding RWE the protocol cannot generate and write the one fact that would move RWE can replace or for RWE evidence-strategy director.

Recommendation

Choose RWE can replace / Only supplement an RCT on this Pharma & Life Sciences / Pharmacovigilance packet (disproportionate reporting signal workbook after a payer demanding RWE the protocol cannot generate). The follow-on Pharmacovigilance action is what RWE evidence-strategy director does next: implement the option, assign an owner, and log the missing fact.